Skip to content

2 results for "Meta-analysis: what did research on addiction find in april 2026?"

Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations.

Research square April 23, 2026 Leah M Salinsky, Joshua L Fox, Kyra C Diaz et al.

Withdrawal from repeated use of methamphetamine and fentanyl together reduces social preference in rats, confirming earlier findings that polysubstance withdrawal impairs social behavior. A single dose of psilocybin did not restore sociability within 24 hours. In the medial prefrontal cortex, psilocybin had opposite effects on CRHR1 gene expression depending on drug history: it decreased expression in control rats but increased it in polysubstance-treated rats. In the nucleus accumbens, polysubstance treatment reduced CRHR1 expression. OPRM1 expression was sex-dependent, with a marked reduction in the nucleus accumbens of females after polysubstance treatment and sex-dependent effects in the medial prefrontal cortex.

The Efficacy and Safety of Ibogaine Treatment for Substance Use Disorders - A Narrative Review

Quality in Sport April 2, 2026 Milena Majchrzyk, Weronika Walendziak, Magdalena Ostaszewska et al.

Ibogaine, an indole alkaloid from the Tabernanthe iboga plant, shows promise for reducing withdrawal and cravings in opioid, cocaine, and alcohol use disorders by modulating serotonin, dopamine, and glutamate systems. However, serious safety risks, especially cardiotoxicity with QT prolongation and potentially fatal arrhythmias, limit its use. Further large-scale randomized controlled trials are needed to better assess its efficacy and safety.